News NICE says no to Genmab cervical cancer therapy Genmab's recently approved therapy for relapsed cervical cancer has been turned down for NHS use in initial NICE guidance.
News BioNTech bigwigs will step down to form new mRNA company The co-founders of mRNA specialist BioNTech – husband and wife team Uğur Şahin and Özlem Türeci – have said they are leaving to set up a new company.
News BMS eyes another celmod filing in myeloma after phase 3 win Bristol Myers Squibb now has positive phase 3 data under its belt for celmod mezigdomide, as it waits for an FDA verdict on lead drug iberdomide.
News Incyte breaks new ground in anal cancer with EU approval Incyte claims EU approval for Zynyz as the first systemic therapy for anal cancer, as J&J gets the nod for wider use of Akeega in prostate cancer.
News Roche's oral SERD flunks phase 3 breast cancer test Roche's recent run of positive study results with breast cancer candidate giredestrant has come to an end with the failure of the persevERA trial.
News Safety concerns prompt Ipsen to pull Tazverik from market Ipsen is voluntarily withdrawing its EZH2 inhibitor Tazverik from sale after a clinical trial suggested a link with secondary blood cancers.
Oncology ASCO 2026: All about DNA damage response, with Luke Piggot Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
